These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The atherosclerotic Yucatan animal model to study the arterial response after balloon angioplasty: the natural history of remodeling. de Smet BJ; van der Zande J; van der Helm YJ; Kuntz RE; Borst C; Post MJ Cardiovasc Res; 1998 Jul; 39(1):224-32. PubMed ID: 9764202 [TBL] [Abstract][Full Text] [Related]
27. The intima. Soil for atherosclerosis and restenosis. Schwartz SM; deBlois D; O'Brien ER Circ Res; 1995 Sep; 77(3):445-65. PubMed ID: 7641318 [No Abstract] [Full Text] [Related]
28. Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups. Foley DP; Melkert R; Umans VA; de Jaegere PP; Strikwerda S; de Feyter PJ; Serruys PW Eur Heart J; 1995 Oct; 16(10):1331-46. PubMed ID: 8746901 [TBL] [Abstract][Full Text] [Related]
29. [Treatment of post-operational restenosis of percutaneous transluminal coronary angioplasty with traditional Chinese medicine]. Zhang Y; Xia X; Su J Zhongguo Zhong Xi Yi Jie He Za Zhi; 1999 Nov; 19(11):701-3. PubMed ID: 11783166 [No Abstract] [Full Text] [Related]
30. Preclinical models of restenosis and their application in the evaluation of drug-eluting stent systems. Perkins LE Vet Pathol; 2010 Jan; 47(1):58-76. PubMed ID: 20080486 [TBL] [Abstract][Full Text] [Related]
31. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772 [TBL] [Abstract][Full Text] [Related]
32. Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model. Keenan RM; Lago MA; Miller WH; Ali FE; Cousins RD; Hall LB; Hwang SM; Jakas DR; Kwon C; Louden C; Nguyen TT; Ohlstein EH; Rieman DJ; Ross ST; Samanen JM; Smith BR; Stadel J; Takata DT; Vickery L; Yuan CC; Yue TL Bioorg Med Chem Lett; 1998 Nov; 8(22):3171-6. PubMed ID: 9873697 [TBL] [Abstract][Full Text] [Related]
34. Lentivirus-mediated RNAi knockdown of the gap junction protein, Cx43, attenuates the development of vascular restenosis following balloon injury. Han XJ; Chen M; Hong T; Zhu LY; He D; Feng JG; Jiang LP Int J Mol Med; 2015 Apr; 35(4):885-92. PubMed ID: 25625334 [TBL] [Abstract][Full Text] [Related]
36. The porcine restenosis model using thermal balloon injury: comparison with the model by coronary stenting. Suzuki Y; Lyons JK; Yeung AC; Ikeno F J Invasive Cardiol; 2008 Mar; 20(3):142-6. PubMed ID: 18316831 [TBL] [Abstract][Full Text] [Related]
37. Intracoronary radiation therapy for prevention of restenosis. Bhargava B; Vodovotz Y; Waksman R Indian Heart J; 1998 Oct; 50 Suppl 1():120-9. PubMed ID: 9824917 [No Abstract] [Full Text] [Related]
38. Recurrent stenosis after coronary angioplasty--current concepts and future direction. Hollman J Indian Heart J; 1991; 43(2):63-8. PubMed ID: 1752616 [No Abstract] [Full Text] [Related]